# Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy

> **NCT01168206** · PHASE3 · UNKNOWN · sponsor: **Lavilabor Natural Products Ltd** · enrollment: 80 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** TK3
- **DIETARY_SUPPLEMENT:** 1 capsule, 3 times per day

## Key facts

- **NCT ID:** NCT01168206
- **Lead sponsor:** Lavilabor Natural Products Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2011-12
- **Final completion:** 2012-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2011-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01168206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01168206, "Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01168206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*